New research published in JACC: Cardiovascular Interventions shows substantial variation between states for non-acute coronary angiograms, percutaneous coronary interventions and coronary artery bypass graft surgeries.

Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.

A new device allows clinicians to remove blood clots from the pulmonary arteries and improve right ventricular function without the use of thrombolytics, according to a late-breaking clinical study presented April 26 at SCAI 2018 in San Diego.

A meta-analysis published April 30 in the New England Journal of Medicine supports radial artery grafts over saphenous vein grafts in coronary artery bypass surgery (CABG), showing lower risks for myocardial infarction, repeat revascularization and graft occlusion.

Operators trained in the hybrid approach to PCI of chronic total occlusions (CTOs) demonstrated technical and procedural success rates of 87 percent and 85 percent, respectively, in a multicenter international trial.

A new meta-analysis found double antithrombotic therapy following PCI for patients with atrial fibrillation (AFib) was associated with 47 percent fewer bleeding events than triple therapy and similar rates of major adverse cardiac events.

The family of a newlywed nurse is suing American Airlines after she fell ill on a flight and died. The cause of her death was determined to be an acute massive pulmonary embolism and cardiogenic shock.

A retrospective study of patients with acute MI complicated by cardiogenic shock presented at SCAI 2018 supported the message from the randomized CULPRIT-SHOCK trial: culprit lesion PCI is associated with lower mortality than multivessel revascularization.